Icosavax Raises $100m To Take RSV, COVID-19 Vaccines Into The Clinic
Platform Enables Vaccines Based On Non-Naturally Occurring VLPs
The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.
